Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV mepolizumab dose-ranging in pediatric eosinophilic esophagitis
2005-006074-10Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mepolizumab in eosinophilic esophagitis (EoE) (3 arms), sponsored by GSK. Primary endpoints: Safety and tolerability during treatment phase and Safety and tolerability during follow-up phase. Started Feb 2006; status: completed.
02
Drugs
mepolizumab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2005-006074-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006074-10.